Navigation Links
AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial,with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product in AM-Pharma's pipeline

BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute Renal Failure. The patients involved were a subgroup of a Phase IIa trial with Alkaline Phosphatase to treat Sepsis.

Plasma creatinine clearance, a marker for renal function, improved by 45% (median) in patients with Acute Renal Failure treated with Alkaline Phosphatase and deteriorated by 25% (median) in patients with Acute Renal Failure treated with placebo, with p values of < 0.05.


In addition, the level of glutathione-S-transferase-A1, a marker for kidney damage, decreased by 70% (median) in AP treated patients, compared to a 200% (median) increase in placebo treated patients, with p values again of < 0.05.


Fifteen patients (10 active, 5 placebo) with Acute Renal Failure were treated for 24 hours as part of a double-blind, randomized, placebo-controlled Phase IIa study in 36 Sepsis patients. The study took place in the Department of Intensive Care Medicine at the Radboud University Medical Centre, Nijmegen, The Netherlands.


Bart Wuurman, CEO of AM-Pharma commented on the positive results, saying: "We are very excited by the results in this Acute Renal Failure subgroup. It shows statistically significant and clinically relevant improvements in a condition that is very difficult to treat, has a high mortality rate and is associated with high costs through long term dialysis treatment. We now plan to explore the use of Alkaline Phosphatase in Acute Renal Failure in a separate study."


- ENDS -

Notes to editors:

About AM-Pharma www.am-pharma.com <




Page: 1 2 3

Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/27/2015)...  Actavis plc (NYSE: ACT ) announced ... Food and Drug Administration (FDA) as a twice-daily, ... syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed ... agonist, a delta receptor antagonist, and a kappa ... "The FDA,s approval of VIBERZI ...
(Date:5/27/2015)... May 27, 2015   Madison Laser Tattoo Removal ... Madison and the surrounding area to offer ... Madison Laser Tattoo Removal is dedicated to bringing a solution ... Wisconsin . "I founded Madison Laser Tattoo ... and return their skin to its natural look," said ...
(Date:5/27/2015)...  Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, today announced that ... laboratory operations in Grand Rapids, Michigan ... , North Carolina.  Sequenom Laboratories, cystic fibrosis carrier ... North Carolina laboratory location.  ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5Madison Laser Tattoo Removal Brings Superior Laser Tattoo Removal Services To Madison, WI With Astanza Duality 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3
(Date:5/27/2015)... 2015 Hundreds of Risperdal lawsuits ... individuals who allegedly suffered gynecomastia (male breast growth) ... the antipsychotic drug continue to move forward in ... Philadelphia Court of Common Pleas. According to court ... trial program, as the third trial involving Risperdal’s ...
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 In ... are getting tighter, it can be challenging for doctors ... for cutting edge treatments. , Austin-based HealthTronics, ... with minimally invasive, mobile medical therapies for clinically sophisticated ... portfolio with the acquisition of Laser Ventures, Inc ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ... for enterprise organizations, announced today that SanMar Corporation ... its time, attendance and point tracking processes for ... United States. , Family-owned since 1971, Seattle-based ... retail, private label, and mill brands. SanMar supplies ...
(Date:5/27/2015)... Little Rock, AR (PRWEB) May 27, 2015 ... and Medix today announce a partnership to provide ... the Medix community. This collaboration seeks to strengthen ... skills measurement through CMSA’s CKP program. The mutually ... focused on identifying individual skills of talent in ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... Ltd, a Pune-based company have jointly come out with ... this at a press conference here on Thursday,// NCL ... the chirally pure S-Amlodipine, a product of their collaborative ... suffering from hypertension. ,Stating that Emcure is ...
... that has receive only a little scientific interest and virtually ... and respiratory health. A study of over 2,000 children ... issue. The study appeared in the January 15, 2002 ... and potassium intakes were associated with lower lung function. ...
... company has finalized development of a digital screening ... of diagnosing melanomas, the third most common cancer ... said that in terms of its ability to ... analysis and computer-aided diagnostic software for SolarScan, which ...
... France observed in a study that red wine drinkers ... "good" cholesterol. This helps show some light on why ... disease. // ,Researchers compared HDL cholesterol levels between ... who are regular drinkers and those who are heavy ...
... at the University of Michigan, made a new study ... patients after head and neck surgery. Ann Arbor say leeches ... who have surgery// to remove cancer in and around the ... ,Doctors say about 15 percent of patients develop obstructions ...
... recall test is able to differentiate those who will get ... a condition of older people - so we can expect ... ages.// Treatments are now available and they seem to work ... a priority. ,Researchers at the University of Toronto ...
Cached Medicine News:Health News:Latest device for identifying Melanomas 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of group A Streptococcal antigen from throat swabs...
Medicine Products: